Catalio Capital Management, LP Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001958125
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q3 2025 · 38 positions · Total reported value $540.93M · Top-10 concentration 55.9% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 63.5% · 13 new · 14 cut · 6 exited
Active Share (vs S&P 500): 98.9% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
In its Q3 2025 13F filing, Catalio Capital Management, LP disclosed 38 equity positions with a combined reported value of $540.93M. The filing implies a moderately concentrated portfolio: its ten largest positions account for 55.9% of reported value. HoldingsHub classifies the profile as Small / Health Tilt / High Turnover.
The largest disclosed positions as of Q3 2025 were LLY ($43.78M), ABBV ($35.85M), BBIO ($32.34M). By sector, the heaviest allocations are Health Care 89.0%, Other 11.0%. Versus the prior quarter, allocation shifted toward Other (+3.6pp) and away from Health Care (-3.6pp).
Versus the prior quarter, Catalio Capital Management, LP opened 13 new positions, trimmed 14 and fully exited 6, a turnover rate of 63.5% of positions. The portfolio's overlap with the prior quarter was 56% of names.
The largest new positions opened in Q3 2025 were ABBV ($35.85M), REGN ($19.87M), ABVX ($13.77M).
Of the 6 positions fully exited versus the prior quarter, the largest were EW ($30.57M), GILD ($25.15M), TEVA ($19.62M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q3 2025)
- ABBV ABBVIE INC · $35.85M
- REGN REGENERON PHARMACEUTICALS · $19.87M
- ABVX ABIVAX SA · $13.77M
- SUPN SUPERNUS PHARMACEUTICALS · $13.72M
- EXAS EXACT SCIENCES CORP COM · $13.62M
- RNAM AVIDITY BIOSCIENCES INC · $11.47M
- GRAL GRAIL INC · $8.16M
- CDTX CIDARA THERAPEUTICS INC COM NEW · $5.11M
Fully Exited (vs previous quarter)
- EW EDWARDS LIFESCIENCES CORP · prev qtr: $30.57M · history
- GILD GILEAD SCIENCES INC · prev qtr: $25.15M
- TEVA TEVA PHARMACEUTICAL INDS LTD · prev qtr: $19.62M
- CORT CORCEPT THERAPEUTICS INC · prev qtr: $17.55M
- HALO HALOZYME THERAPEUTICS INC · prev qtr: $9.96M
- WGS GENEDX HOLDINGS CORP · prev qtr: $5.68M
- REPL REPLIMUNE GROUP INC · prev qtr: $3.07M
- ZBIO ZENAS BIOPHARMA INC · prev qtr: $2.09M
Insider Transactions (Form 4)
Latest Catalio Capital Management, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-10-16 | Conversion | Iambic Therapeutics, Inc. | 742,546 | — | SEC filing |
| 2026-10-16 | Conversion | Iambic Therapeutics, Inc. | 1,458,290 | — | SEC filing |
| 2026-10-16 | Conversion | Iambic Therapeutics, Inc. | 1,995,749 | — | SEC filing |
Fund Profile
Catalio Capital Management, LP is an SEC-registered 13F filer based in New York, NY, United States. As of Q3 2026 it reported 46 US equity positions with a combined value of $535.82M. HoldingsHub carries 8 quarters of its filings (Q4 2024–Q3 2026).
Firm Snapshot
- Headquarters: NEW YORK, NY, United States
- SEC registration: 801-121976 (status: Approved), registered 2021-07-30
- Regulatory AUM (Form ADV): $1.93B as of 2026-03-31
- Client mix (by RAUM): pension and profit-sharing plans 78%, pooled investment vehicles 13%
- Manages 23 private funds, of which 1 hedge funds
Portfolio Structure
- 46 positions · $535.82M reported value (Q3 2026)
- Top 10 holdings = 48.7% of reported value
- Largest position: AVLN (AVALYN PHARMACEUTICALS INC) at 9.0%
- Average position size: $11.65M
Sector Tilt
- Health Care 96.3%
- Industrials 2.8%
- (classified holdings cover 99% of value)
Quarterly Activity
- Q3 2026: 13 new, 13 added, 14 reduced, 6 exited
- 6 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
57.38K | $43.78M | 8.09% | Add | |
| 2 |
|
154.83K | $35.85M | 6.63% | New | |
| 3 |
|
622.73K | $32.34M | 5.98% | Reduce | |
| 4 |
|
71.34K | $31.91M | 5.90% | Add | |
| 5 |
|
144.95K | $28.82M | 5.33% | Reduce | |
| 6 |
|
418.25K | $28.27M | 5.23% | Add | |
| 7 |
|
667.62K | $26.27M | 4.86% | Reduce | |
| 8 |
|
262.97K | $25.67M | 4.75% | Add | |
| 9 |
|
1.61M | $24.84M | 4.59% | Reduce | |
| 10 |
|
451.58K | $24.82M | 4.59% | Reduce | |
| 11 |
|
148.37K | $23.88M | 4.42% | Add | |
| 12 |
|
35.34K | $19.87M | 3.67% | New | |
| 13 |
|
651.81K | $18.25M | 3.37% | Reduce | |
| 14 |
|
282.94K | $16.52M | 3.05% | Reduce | |
| 15 |
|
216.53K | $14.31M | 2.65% | Add | |
| 16 |
|
162.14K | $13.77M | 2.54% | New | |
| 17 |
|
287.09K | $13.72M | 2.54% | New | |
| 18 |
|
248.99K | $13.62M | 2.52% | New | |
| 19 |
|
1.13M | $13.28M | 2.46% | Add | |
| 20 |
|
884.89K | $13.24M | 2.45% | Reduce | |
| 21 |
|
263.26K | $11.47M | 2.12% | New | |
| 22 |
|
684.51K | $10.03M | 1.85% | Add | |
| 23 |
|
291.26K | $8.76M | 1.62% | Add | |
| 24 |
|
5.21M | $8.29M | 1.53% | Add | |
| 25 |
|
137.93K | $8.16M | 1.51% | New | |
| 26 |
|
1.50M | $6.53M | 1.21% | Reduce | |
| 27 |
|
294.36K | $5.54M | 1.02% | Hold | |
| 28 |
|
53.33K | $5.11M | 0.94% | New | |
| 29 |
|
586.91K | $3.52M | 0.65% | Hold | |
| 30 |
|
1.06M | $2.75M | 0.51% | New | |
| 31 |
|
118.28K | $1.67M | 0.31% | Reduce | |
| 32 |
|
528.99K | $1.25M | 0.23% | Hold | |
| 33 |
|
196.86K | $1.04M | 0.19% | Hold | |
| 34 |
|
684.54K | $992.58K | 0.18% | Reduce | |
| 35 |
|
133.13K | $954.55K | 0.18% | Reduce | |
| 36 |
|
142.98K | $935.12K | 0.17% | Reduce | |
| 37 |
|
12.01K | $752.91K | 0.14% | New | |
| 38 |
|
14.72K | $139.09K | 0.03% | Hold | |
FAQ
What did Catalio Capital Management, LP buy in 2025-Q3?
In its 2025-Q3 13F filing, Catalio Capital Management, LP reported 38 equity positions worth $540.93M in aggregate; its largest disclosed positions were LLY ($43.78M), ABBV ($35.85M), BBIO ($32.34M).
How large is Catalio Capital Management, LP's portfolio?
Catalio Capital Management, LP reported $540.93M of long equity holdings across 38 positions as of 2025-Q3. Top-10 holdings account for 55.9% of reported value.
What is Catalio Capital Management, LP's investment style?
HoldingsHub classifies the portfolio as Small / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.